AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Processa Pharmaceuticals, Inc.
Video analysis: PCSA
All videosNo video analysis for this stock yet. Request one from our team.
News: PCSA
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
VERO BEACH, FL, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases, today announced its participation in two upcoming investor conferences.
Processa Pharmaceuticals, Inc. (PCSA) M&A Call Prepared Remarks Transcript
Processa Pharmaceuticals, Inc. (PCSA) M&A Call Prepared Remarks Transcript
Processa buys Vidya Therapeutics, raises $200 million for drug trials
Processa Pharmaceuticals said on Wednesday it acquired privately held Vidya Therapeutics in an all-stock deal, gaining access to its lead candidate being developed to target diseases involving the immune system.
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC.
Acquisition brings into Processa's pipeline Vidya's lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class Bruton's tyrosine kinase inhibitor (BTKi) designed to overcome the efficacy and safety limitations of early-generation BTKi programs Concurrent oversubscribed private placement financing of approximately $200 million committed by a syndicate of leading healthcare institutional investors and mutual funds Private placement proceeds are expected to fund operations into the second half of 2029 and through key clinical milestones, including top-line data from Phase 2 proof-of-concept studies for food allergy, chronic spontaneous urticaria (CSU), and relapsing multiple sclerosis (RMS) Processa to host investor webcast on July 29, 2026, at 8:30 a.m. ET VERO BEACH, FL, July 29, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Processa) (Nasdaq: PCSA) today announced it has acquired Vidya Therapeutics, Inc. (Vidya), a clinical-stage biotechnology company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases with an initial focus on potentially best-in-class BTK inhibition in food allergy, chronic spontaneous urticaria and relapsing multiple sclerosis.
